BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
at www.tipranks.com (Thu, 9-Jul 6:06 AM)
BioAge’s BGE-102 Achieves Over 85% Reduction in hsCRP, Setting New Benchmark in Inflammation Trials
Market Chameleon (Tue, 21-Apr 7:35 AM)
BioAge Labs Highlights Progress in Metabolic Aging Therapeutics Ahead of Needham Conference Presentation
Market Chameleon (Tue, 14-Apr 9:22 AM)
